Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Best IPOs for Long-Term Investment: Not Just Listing Gains

By Jagat Joshi
April 11, 2026

IPOs are often known for providing short-term listing gains. It allows investors to have an opportunity to earn quick revenue. While many Initial Public offerings (IPO) have offered outstanding returns on listing day as well as in the long term. However, not all IPOs have performed well and have delivered disappointing returns.

Today, Many investors prefer IPO investment with a long-term perspective rather than just quick listing gains. Whether it is a Mainboard IPO or an SME IPO, long-term investors aim to participate in businesses that can offer sustainable value over time. For this reason, we wrote this article for investors who believe in the long-term growth of the company, rather than immediate listing gains. In this blog, we will give you the names of current and upcoming IPOs you can apply for long-term investment.

What factors matter for Long-term Listing gains?

Most of the IPOs do offer incredible listing gains, but do not turn into long-term stocks. Despite attracting significant investor interest at the time of listing, a large number of these stocks underperform. So, how do you decide if the IPO is great for long-term investors? Making the right IPO investment requires a lot of research and a deep understanding of the company’s fundamentals. Here are some of the key factors that help long-term success.

Consistent growth in revenue, profit, and cash flow.
An experienced management team and a strong promoter group.
Strong industry position.
Reasonable Valuation of IPO attracts long-term investors.
Good use of IPO proceeds.
Fulfils its post-listing growth commitments.

Best Upcoming IPOs in 2026 for Long-Term Listing Gains

Several large, established mainboard IPO are planning to hit the stock market in 2026, offering investors a chance to benefit from potential listing gains and long-term growth.

Reliance Jio: Nothing better than to start the list with one of the most awaited IPO of the year, Reliance Jio. Reliance Jio platforms, the telecom and digital arm of Reliance Industries Ltd, is expected to hit the IPO market in 2026. With a potential valuation of up to $170 billion, this IPO can be the biggest in history. Due to its strong market position and wide customer reach, investors can apply for this IPO for long-term investment.

National Stock Exchange: Another most anticipated IPO, the National Stock Exchange (NSE) is also preparing its prospectus and is expected to launch in 2026. The National Stock Exchange (NSE) is India’s most important stock exchange, based in Mumbai. According to the source, the company is planning to raise ₹47,500 crore, bringing the company’s total valuation to ₹4.75 lakh crore. Impressive valuations and strong financial numbers suggest a strong long-term investment.

Flipkart: Nothing grabs investor attention like the Flipkart IPO, one of the most talked-about IPO expected to make its debut in 2026. Incorporated in 2007, Flipkart is one of the leading E-commerce websites owned by Walmart and is looking for a valuation of $60-70 billion. Moreover, recently, they also acquired the approval from NCLT to shift their legal entity from Singapore back to India.

PhonePe: PhonePe is India’s leading digital payment platform and has already filed its confidential draft papers with SEBI, expecting to hit the market in 2026. This Walmart-backed company is planning to raise around ₹12,000 crore via its IPO. Its large customer base and growing revenues may offer significant long-term potential.

SBI Mutual Fund: India’s largest asset management company, SBI Mutual Fund, is also gearing up to float its IPO in 2026. A Joint Venture between SBI and AMUNDI (France), the company has 38 years of experience in fund management. The strong fundamentals and exposure to the growing Indian mutual fund industry make it attractive for long-term investors.

Zepto: India’s quick commerce unicorn, Zepto, is also planning to launch its IPO, already filed its confidential draft papers with SEBI on December 26. The key details like IPO dates, IPO price, and size are yet to be announced. Zepto is one of the leading quick commerce companies that claims to deliver groceries and everyday essentials in just 10 minutes. As per the sources, Zepto is going to launch an IPO, as the board has approved an IPO of ₹11,000 crore. Wherein the fresh issue and OFS both would be included.

OYO: OYO hotels and homes, also known as OYO rooms, filed its confidential DRHP on December 31, 2025, to raise ₹6,650 crore IPO. OYO is a leading Indian multinational hospitality company, owned by PRISM, which already filed its draft papers in 2021 and withdrew due to s due to the Russia-Ukraine conflict. Its modern, technology-driven platform supports long-term listing gains.

Best Recent IPOs for Long-term Listing Gains

Waree Energies: India’s leading solar PV module manufacturer, Waree Energies. In 2024, this IPO attracted strong investor interest with a listing roughly 66–70% above the IPO price of ₹1503. Since then, the stock has continued to rise and is now trading around ₹3,053 per share, almost double the IPO price.

Aditya Infotech: Aditya Infotech, a growing video security and surveillance products company, launched its IPO in 2025 with a price of ₹675 per share. Not only does it list with a 50% premium, but it is currently trading near ₹1,500 per share, which points to strong investor confidence and its potential as a long-term growth stock.

Oriana Power: One of the leading solar energy solutions providers, Oriana Power, launched its IPO in 2023 with ₹118 per share and listed with 150% listing gains. Since then, the stock has risen to nearly ₹2,269 per share, making it a trusted company for long-term investors who believe in sustainable energy solutions.

ICICI Prudential AMC: One of the latest listed IPO, ICICI Prudential AMC, launched its IPO in December 2025 with a price of ₹2,165 and listed at around ₹2,600. It is India’s largest Asset Management Company. The consistent financial profitability and strong AUM growth make it an attractive long-term investment stock.

Note: Investing in IPOs involves risk, and long-term performance depends on many factors, like valuation, market sentiment, and business growth. Take this article as an indicator of potential opportunities and not guaranteed profits. Make sure to buy/sell shares at your own risk.

FAQs

1. What is a long-term IPO investment?

A long-term IPO investment means buying shares of a newly listed company with the intention of holding it over several years rather than for listing gains.

2. Are all IPOs good for long-term investment?

No, many IPOs do offer great short-term listing gains but fail to deliver long-term growth. We recommend that investors analyze the company’s fundamentals, financials, and growth prospects before investing for the long term.

3. Which IPO is best to buy for the long term?

Reliance Jio, NSE, Flipkart, Zepto, and SBI Mutual Fund are some of the largest reputable companies to buy for the long term.

4. How long should I hold IPO shares for long-term returns?

Analysts generally recommend holding the shares for at least 3-5 years or more to benefit from the company’s long-term growth.

5. How can I research IPOs for long-term investment?

By analysing the company’s fundamentals, growth prospects, strengths, industry position, analyst reports, and expert opinions, one can determine if the IPO has potential for long-term wealth.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.